The answer is nobody really knows exactly how much was spent on Bisantrene in its former life. We do know that around 2000 patients were given Bisantrene and even at $100K per patient that works out at $200 million. This doesn’t take into account all the preclinical work that was done.
The real value of all the past trials today is not how much was spent from the 1970s to 1990s, but how much we know about Bisantrene. To replicate this work today would probably cost you in excess of US$300 million if you could get access to the patients, which in the case of AML would be impossible.
-
- There are more pages in this discussion • 11,844 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.34 |
Change
-0.015(1.11%) |
Mkt cap ! $231.9M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.36 | $1.31 | $132.3K | 98.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.34 | 10069 | 2 |
View Market Depth
| Last trade - 15.54pm 20/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |